Table 2.
Characteristics of male and female patients with SZ.
| Male | Female | F or X2 | p-value | |
|---|---|---|---|---|
| Age | 51.5 ± 9.1 | 48.3 ± 11.7 | 4.4 | 0.04 |
| Education (years) | 9.6 ± 2.5 | 10.4 ± 2.6 | 4.6 | 0.032 |
| Age of onset (years) | 23.9 ± 5.5 | 26.0 ± 7.2 | 4.75 | 0.031 |
| Antipsychotic types (typicals/atypicals) | 24/83 | 13/56 | 0.33 | 0.57 |
| Antipsychotic dose (CPZ equivalents) | 411.2 ± 193.8 | 437.6 ± 251.9 | −0.76 | 0.45 |
| Duration of current antipsychotic treatment | 66.6 ± 68.5 | 46.3 ± 68.3 | 1.75 | 0.08 |
| Duration of current antipsychotic treatment | 66.6 ± 68.5 | 46.3 ± 68.3 | 1.75 | 0.08 |
| Number of hospitalizations | 3.9 ± 3.7 | 3.5 ± 2.4 | 0.73 | 0.46 |
| PANSS | ||||
| Positive symptom scale | 12.0 ± 4.7 | 14.6 ± 6.2 | −3.20 | 0.002 |
| Negative symptom scale | 23.0 ± 6.8 | 20.4 ± 9.0 | 2.05 | 0.04 |
| General psychopathology scale | 27.3 ± 4.9 | 27.9 ± 6.0 | −0.66 | 0.51 |
| Total score | 62.3 ± 12.3 | 62.9 ± 15.3 | −0.50 | 0.62 |
Mean ± SD.
CPZ chlorpromazine, PANSS the Positive and Negative Syndrome Scale.